SCHEMBL18094459

SCHEMBL18094459

CN1CCN(c2cccc(-c3nsc(NC(=O)c4ccc(C(F)(F)F)cc4)n3)n2)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MAPT P10636 1/20 0.46
▸ ALK Q9UM73 2/20 0.44
▸ BTK Q06187 1/20 0.43
▸ SRPK1 Q96SB4 1/20 0.42
▸ ADORA3 P0DMS8 4/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MPL P40238 1/20 0.41
▸ EIF2AK4 Q9P2K8 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ CDK5R1 Q15078 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18094536 0.89 MAPT (0.44) SMN1; SMN2MAPTADORA3RXFP1MPL
SCHEMBL18094580 0.87 GPR119 (0.46) SMN1; SMN2MAPTEIF2AK4
SCHEMBL18094555 0.82 SMN1; SMN2 (0.52) SMN1; SMN2MAPTBTKRAB9A
SCHEMBL18094454 0.81 SMN1; SMN2 (0.49) SMN1; SMN2MAPTALKBTKSRPK1
SCHEMBL18094552 0.80 MAPT (0.52) MAPTADORA3RXFP1MPLRAB9A
SCHEMBL18094538 0.77 ADORA3 (0.60) SMN1; SMN2MAPTADORA3RXFP1MPL
SCHEMBL18094482 0.75 TRPV1 (0.60) ADORA3RXFP1
SCHEMBL18094559 0.74 NTRK1 (0.49) SMN1; SMN2MAPTADORA3RXFP1MPL
SCHEMBL18230420 0.74 TRPV4 (0.70) SMN1; SMN2MAPTBTKADORA3
SCHEMBL18094571 0.73 LRRK2 (0.46) SMN1; SMN2MAPTSRPK1ADORA3MPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170202849-A1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. 2017-07-20 — — US claimed
US-9643963-B2 Antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2017-05-09 — — US claimed
US-20160280700-A1 ANTIPARASITIC COMPOUNDS SNAPDRAGON CHEMISTRY, INC. 2016-09-29 — — US claimed
US-20170202849-A1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. 2017-07-20 — — US disclosed
US-9643963-B2 Antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2017-05-09 — — US disclosed
US-20160280700-A1 ANTIPARASITIC COMPOUNDS SNAPDRAGON CHEMISTRY, INC. 2016-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280700-A1 ANTIPARASITIC COMPOUNDS TPP2, TPP1, SERPINB1 SMN1; SMN2 2168/4885MAPT 2921/4885ALK 4858/4885
US-20170202849-A1 ANTIPARASITIC COMPOUNDS TPP2, TPP1, SERPINB1 SMN1; SMN2 2168/4885MAPT 2921/4885ALK 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback